Business
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
IMCIVREE now publicly covered for weight management due to Bardet-Biedl syndrome (BBS) in Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and
About this update from Rhythm Pharmaceuticals, Inc.
[{"type":"text","content":"IMCIVREE now publicly covered for weight management due to Bardet-Biedl syndrome (BBS) in Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and under NIHB\nBOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it has entered into Product Listing Agreements in the provinces of Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and with the Federal Non-Insured Health Benefits (NIHB) Program for the public reimbursement of IMCIVREE for weight management in eligible adult and pediatric patients aged 6 years and older with clinically or genetically confirmed Bardet-Biedl syndrome (BBS) and obesity. “These listing agreements for IMCIVREE mark a significant milestone for individuals living with obesity due to Bardet-Biedl syndrome,” said Prof. Andrea M. Haqq, M.D., Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta. “Patients and families in these provinces can now access a treatment that addresses a root cause of their disease, offering hope and improved quality of life.” IMCIVREE was approved by Health Canada in May 2023 following priority review and was recently added to the common list of new drugs for rare diseases, as part of the Government of Canada's National Strategy for Drugs for Rare Diseases. The Common Drug List ensures that the National Strategy for Drugs for Rare Diseases provides the greatest possible benefit to all patients with rare diseases. “These agreements are an important recognition of the substantial burden of obesity associated with this rare disease,” said Carol Stiff, General Manager, Rhythm Canada. “We continue to engage with all provinces and territories to work toward equitable access in Canada for all patients living with obesity due to BBS.” About Bardet-Biedl Syndrome BBS is a rare autosomal recessive ciliopathy that presents with a variety of symptoms that evolve over time, including hyperphagia, early-onset, severe obesity, visual impairment, polydactyly, genital abnormalities, renal dysfunction, and cognitive impairment. About Rhythm PharmaceuticalsRhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and the...